Valneva SE (ENXTPA: VLA)
Health Care · Biotechnology · FR
€2.89
+0.73% today · -26.3% 1Y
Valneva SE (ENXTPA: VLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $640.49M and employs 620 people.
Over the last twelve months the share price has lost 26.3%, trading between 2.03 and 5.34.
Tweenvest scores Valneva SE across four factors: quality 48/100, value 54/100, growth 65/100. Its strongest factor is growth.
VLA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $640.49M
- Revenue (TTM)
- $163.30M
- P/E
- —
- EPS
- -0.88
- Dividend yield
- —
- Beta (5Y)
- 1.35
- 52-week high
- €5.34
- 52-week low
- €2.03
- Avg volume (3M)
- —
- Shares outstanding
- 189.65M
- Employees
- 620
- Next earnings
- —
About Valneva SE
Valneva SE is a specialized biotechnology company focused on developing and bringing to market preventative vaccines for infectious diseases with significant unmet medical needs. Their commercial offerings for travelers include IXIARO, a vaccine against Japanese encephalitis, and DUKORAL, an oral vaccine designed to protect against diarrhea caused by Vibrio cholera and specific heat-labile toxin-producing Enterotoxigenic Escherichia coli. The company also progressed VLA2001, a vaccine candidate targeting SARS-CoV-2. In its development pipeline, Valneva has VLA15, a Lyme disease vaccine candidate that has concluded Phase II clinical trials, and VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III evaluation. The company distributes its products across the United States, Canada, various European nations including Germany, Austria, the Nordics, and the United Kingdom, as well as other global markets. Valneva SE has established strategic partnerships, notably with Pfizer, Inc. for the joint development and commercialization of its Lyme disease vaccine, and with Instituto Butantan for the creation, manufacturing, and marketing of a single-shot chikungunya vaccine. The company was established in 1998 and operates from its headquarters in Saint-Herblain, France.
- ISIN
- FR0004056851
- Founded
- 1998
- Listed since
- Jun 29, 2007
- Exchange
- Euronext Paris
- Currency
- EUR
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.09 | -0.46% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.